Optimi Health welcomes Australia TGA move to broaden psychedelic-assisted therapy access

• Optimi responded to Australia’s TGA final recommendations updating the Authorized Prescriber scheme for psilocybin, MDMA under psychedelic-assisted therapy.
• Framework broadened therapist eligibility, widened acceptable treatment settings beyond hospitals, kept AP psychiatrists on-site during medicine administration.
• Optimi said no serious adverse events have been reported under the scheme since December 2025, citing aggregated TGA data.
• Reimbursement expanded beyond private pay to include public programs such as DVA, NDIS, WorkCover, alongside Medibank coverage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605290830PRIMZONEFULLFEED9728638) on May 29, 2026, and is solely responsible for the information contained therein.